Recombinant SARS-CoV-2 Nucleocapsid His Protein, CF

Sf21 Insect Cell Expressed, Over 95% Purity
Catalog # Availability Size / Price Qty
10474-CV-050
10474-CV-01M
Best Seller
Recombinant SARS-CoV-2 Nucleocapsid His Protein SDS-PAGE
1 Image
Product Details
Citations (5)
FAQs
Reviews (1)

Recombinant SARS-CoV-2 Nucleocapsid His Protein, CF Summary

Product Specifications

Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Bioassay data are not available.
Source
Spodoptera frugiperda, Sf 21 (baculovirus)-derived sars-cov-2 Nucleocapsid protein
Met1-Ala419, with a C-terminal 6-His tag
Accession #
N-terminal Sequence
Analysis
Ser2
Predicted Molecular Mass
46 kDa
SDS-PAGE
44-53 kDa, under reducing conditions

Product Datasheets

You must select a language.

x

10474-CV

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

10474-CV

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

SDS-PAGE Recombinant SARS-CoV-2 Nucleocapsid His Protein SDS-PAGE View Larger

2 μg/lane of Recombinant SARS-CoV-2 Nucleocapsid His Protein (Catalog # 10474-CV) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 44-53 kDa.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: Nucleocapsid

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N) (1).  While the S, E and M proteins build up the viral envelop, the N protein is involved transcription, replication and packaging of the viral RNA genome into a helical ribonucleocapsid (RNP) (2, 3).  The SARS-CoV-2 N protein is a ~45 kDa protein composed of two independent structural domains connected by a linker region. The N-terminal region contains an RNA binding domain, the linker region interacts with the M protein and the C-terminal region contains a self-association domain (2,3). The SARS-CoV2 N protein shares 91% and 47% amino acid sequence identity with SARS-CoV-1 and MERS N protein, respectively.  The SARS-CoV-2 N protein displays VSR (viral suppressor of RNA interference) activity in mammalian cells (4). In addition, the N protein is an abundant protein during coronavirus infection and displays high immunogenic activity (5, 6), so it has been used to develop serological diagnostic kit for Covid-19 IgM and IgG antibody tests (7).

References
  1. Wu, F. et al. (2020) Nature 579:265.
  2. Chang, C. K. et al. (2006) J. Biomed. Sci. 13:59.
  3. Hurst, K. R. et al. (2009) J. Virol. 83:7221.
  4. Mu, J. et al. (2020) Sci. China Life Sci. doi: 10.1007/s11427-020-1692-1.
  5. Che, X. Y. et al. (2004) J. Clin. Microbiol. 42:2629.
  6. Guan, M. et al. (2004) Clin. Diagn. Lab. Immunol. 11:287.
  7. Liu, W. et al. (2020) J. Clin. Microbiol. doi: 10.1128/JCM.00461-20.
Long Name
Nucleocapsid Protein
Entrez Gene IDs
918763 (HCoV-229E); 3200423 (HCoV-HKU1); 2943504 (HCoV-NL63); 39105221 (HCoV-OC43); 14254601 (MERS-CoV); 1489678 (SARS-CoV); 43740575 (SARS-CoV-2)
Alternate Names
N Protein; Nucleocapsid protein; Nucleocapsid; ORF9a protein

Citations for Recombinant SARS-CoV-2 Nucleocapsid His Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

5 Citations: Showing 1 - 5
Filter your results:

Filter by:

  1. Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2 mRNA vaccination depends on prior infection history
    Authors: Kiszel, P;Sík, P;Miklós, J;Kajdácsi, E;Sinkovits, G;Cervenak, L;Prohászka, Z;
    Scientific reports
    Species: Human
    Sample Types: Recombinant Protein
    Applications: ELISA Capture
  2. A new multiplex SARS-CoV-2 antigen microarray showed correlation of IgG, IgA, and IgM antibodies from patients with COVID-19 disease severity and maintenance of relative IgA and IgM antigen binding over time
    Authors: ML Berre, T Paulov?áko, CM Verissimo, S Doyle, JP Dalton, C Masterson, ER Martínez, L Walsh, C Gormley, JG Laffey, B McNicholas, AJ Simpkin, M Kilcoyne
    PLoS ONE, 2023-03-30;18(3):e0283537.
    Species: Human
    Sample Types: Serum
    Applications: Binding
  3. A new multiplex SARS-CoV-2 antigen microarray showed correlation of IgG, IgA, and IgM antibodies from patients with COVID-19 disease severity and maintenance of relative IgA and IgM antigen binding over time
    Authors: ML Berre, T Paulov?áko, CM Verissimo, S Doyle, JP Dalton, C Masterson, ER Martínez, L Walsh, C Gormley, JG Laffey, B McNicholas, AJ Simpkin, M Kilcoyne
    PLoS ONE, 2023;18(3):e0283537.
    Species: Human
    Sample Types: Serum
    Applications: Binding
  4. Evidence, detailed characterization and clinical context of complement activation in acute multisystem inflammatory syndrome in children
    Authors: G Sinkovits, J Schnur, L Hurler, P Kiszel, ZZ Prohászka, P Sík, E Kajdácsi, L Cervenak, V Maráczi, M Dávid, B Zsigmond, É Rimanóczy, C Bereczki, L Willems, EJM Toonen, Z Prohászka
    Scientific Reports, 2022-11-17;12(1):19759.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: ELISA Standard
  5. Calcium dobesilate reduces SARS-CoV-2 entry into endothelial cells by inhibiting virus binding to heparan sulfate
    Authors: Y Kiyan, A Schultalbe, E Chernobriv, S Tkachuk, S Rong, N Shushakova, H Haller
    Scientific Reports, 2022-10-07;12(1):16878.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Bioassay

FAQs

  1. What is the strain/variant of Recombinant SARS-CoV-2 Nucleocapsid His Protein, CF (Catalog # 10474-CV)?

    • Catalog # 10474-CV references accession # YP_009724397.2 which is the Wuhan strain (also known as Wuhan-Hu-1).

View all Proteins and Enzyme FAQs

Reviews for Recombinant SARS-CoV-2 Nucleocapsid His Protein, CF

Average Rating: 4 (Based on 1 Review)

5 Star
0%
4 Star
100%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Recombinant SARS-CoV-2 Nucleocapsid His Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Recombinant SARS-CoV-2 Nucleocapsid His Protein, CF
By Scott Scarneo on 06/20/2022
Application: In vitro bioactivity in cell culture
Reason for Rating: Stimulated immune cells evidenced by increased cytokine expression.